An increasing number of patients with HER2-positive breast cancer are receiving neoadjuvant therapy [6], making it difficult to distinguish between tumor and chemotherapy-induced fibrosis and to obtain clear resection margins [7, 8]. This evidence concerns the gene ERBB2 and neoplasm.